2024 ICD-10-CM Diagnosis Code T44.3X6D

Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter

ICD-10-CM Code:
T44.3X6D
ICD-10 Code for:
Underdosing of oth parasympatholytics and spasmolytics, subs
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Not chronic
Code Navigator:

Code Classification

  • Injury, poisoning and certain other consequences of external causes
    (S00–T88)
    • Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
      (T36-T50)
      • Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system
        (T44)

T44.3X6D is a billable diagnosis code used to specify a medical diagnosis of underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024. The code is exempt from present on admission (POA) reporting for inpatient admissions to general acute care hospitals.

This code describes a circumstance which influences the patient's health status but not a current illness or injury. The code is unacceptable as a principal diagnosis.

T44.3X6D is a subsequent encounter code, includes a 7th character and should be used after the patient has completed active treatment for a condition like underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics. According to ICD-10-CM Guidelines a "subsequent encounter" occurs when the patient is receiving routine care for the condition during the healing or recovery phase of treatment. Subsequent diagnosis codes are appropriate during the recovery phase, no matter how many times the patient has seen the provider for this condition. If the provider needs to adjust the patient's care plan due to a setback or other complication, the encounter becomes active again.

Clinical Classification

Clinical Information

  • Atropine

    an alkaloid, originally from atropa belladonna, but found in other plants, mainly solanaceae. hyoscyamine is the 3(s)-endo isomer of atropine.
  • Atropine Derivatives

    analogs and derivatives of atropine.
  • Hyoscyamine

    the 3(s)-endo isomer of atropine.
  • Benactyzine

    a centrally acting muscarinic antagonist. benactyzine has been used in the treatment of depression and is used in research to investigate the role of cholinergic systems on behavior.
  • Benztropine

    a centrally active muscarinic antagonist that has been used in the symptomatic treatment of parkinson disease. benztropine also inhibits the uptake of dopamine.
  • Biperiden

    a muscarinic antagonist that has effects in both the central and peripheral nervous systems. it has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. it has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
  • Cyclopentolate

    a parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
  • Dexetimide

    a muscarinic antagonist that has been used to treat neuroleptic-induced parkinsonism. benzetimide is the (-)-enantimorph of dexetimide.
  • Dicyclomine

    a muscarinic antagonist used as an antispasmodic and in urinary incontinence. it has little effect on glandular secretion or the cardiovascular system. it does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.
  • Dyphylline

    a theophylline derivative with broncho- and vasodilator properties. it is used in the treatment of asthma, cardiac dyspnea, and bronchitis.
  • Flavoxate

    a drug that has been used in various urinary syndromes and as an antispasmodic. its therapeutic usefulness and its mechanism of action are not clear. it may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.
  • Gefarnate

    a water insoluble terpene fatty acid used in the treatment of gastrointestinal ulcers; it facilitates the healing and function of mucosal tissue.
  • Glycopyrrolate

    a muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.
  • Hyoscyamus

    a plant genus of the family solanaceae which contains tropanes.
  • Methantheline

    a quaternary ammonium compound that acts as an antimuscarinic agent. it has been used in the treatment of peptic ulcer, in gastrointestinal disorders associated with smooth muscle spasm, and in the management of urinary incontinence, and may also be used for the treatment of hyperhidrosis.
  • Papaverine

    an alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. it is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. the mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.
  • Procyclidine

    a muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
  • Propantheline

    a muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. at high doses it has nicotinic effects resulting in neuromuscular blocking.
  • Butylscopolammonium Bromide

    antimuscarinic quaternary ammonium derivative of scopolamine used to treat cramps in gastrointestinal, urinary, uterine, and biliary tracts, and to facilitate radiologic visualization of the gastrointestinal tract.
  • N-Methylscopolamine

    a muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.
  • Scopolamine

    an alkaloid from solanaceae, especially datura and scopolia. scopolamine and its quaternary derivatives act as antimuscarinics like atropine, but may have more central nervous system effects. its many uses include an anesthetic premedication, the treatment of urinary incontinence and motion sickness, an antispasmodic, and a mydriatic and cycloplegic.
  • Scopolamine Derivatives

    analogs or derivatives of scopolamine.
  • Tolperisone

    a centrally acting muscle relaxant that has been used for the symptomatic treatment of spasticity and muscle spasm. (from martindale, the extra pharmacopoeia, 30th ed, p1211)
  • Trihexyphenidyl

    one of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic.
  • Trimebutine

    proposed spasmolytic with possible local anesthetic action used in gastrointestinal disorders.
  • Tropicamide

    one of the muscarinic antagonists with pharmacologic action similar to atropine and used mainly as an ophthalmic parasympatholytic or mydriatic.

Coding Guidelines

Underdosing refers to taking less of a medication than is prescribed by a provider or a manufacturer's instruction. Codes for underdosing should never be assigned as principal or first-listed codes. If a patient has a relapse or exacerbation of the medical condition for which the drug is prescribed because of the reduction in dose, then the medical condition itself should be coded.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44). Use the following options for the aplicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10-CM Code Edits are applicable to this code:

  • Unacceptable principal diagnosis - There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)

T44.3X6D is exempt from POA reporting - The Present on Admission (POA) indicator is used for diagnosis codes included in claims involving inpatient admissions to general acute care hospitals. POA indicators must be reported to CMS on each claim to facilitate the grouping of diagnoses codes into the proper Diagnostic Related Groups (DRG). CMS publishes a listing of specific diagnosis codes that are exempt from the POA reporting requirement. Review other POA exempt codes here.

CMS POA Indicator Options and Definitions

POA IndicatorReason for CodeCMS will pay the CC/MCC DRG?
YDiagnosis was present at time of inpatient admission.YES
NDiagnosis was not present at time of inpatient admission.NO
UDocumentation insufficient to determine if the condition was present at the time of inpatient admission.NO
WClinically undetermined - unable to clinically determine whether the condition was present at the time of inpatient admission.YES
1Unreported/Not used - Exempt from POA reporting. NO

Convert T44.3X6D to ICD-9-CM

  • ICD-9-CM Code: -
    No Map Flag -

Table of Drugs and Chemicals

The parent code T44.3X6 of the current diagnosis code is referenced in the Table of Drugs and Chemicals, this table contains a classification of drugs, industrial solvents, corrosive gases, noxious plants, pesticides, and other toxic agents.

According to ICD-10-CM coding guidelines it is advised to do not code directly from the Table of Drugs and Chemicals, instead always refer back to the Tabular List when doing the initial coding. Each substance in the table is assigned a code according to the poisoning classification and external causes of adverse effects. It is important to use as many codes as necessary to specify all reported drugs, medicinal or chemical substances. If the same diagnosis code describes the causative agent for more than one adverse reaction, poisoning, toxic effect or underdosing, utilize the code only once.

Substance Poisoning
Accidental
(unintentional)
Poisoning
Accidental
(self-harm)
Poisoning
Assault
Poisoning
Undetermined
Adverse
effect
Underdosing
AdiphenineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AlverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Ambutonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AminopentamideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AmprotropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AniscoropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Anisotropine methyl-bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Anticholinergic NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Antimuscarinic NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ArtaneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
AtropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Atropine
  »derivative
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Atropine
  »methonitrate
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]
  »alkaloids
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]
  »extract
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Belladonna [See Also: Nightshade]
  »herb
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenactyzineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenaprizineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenzhexolT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Benzilonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BenztropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Benztropine
  »anticholinergic
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Benztropine
  »antiparkinson
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Bevonium metilsulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BiperidenT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
BornaprineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ButethamateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Butropium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CamylofinT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CaramiphenT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Carpronium chlorideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ChlorbenzoxamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Cimetropium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Clidinium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ClorotepineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CogentinT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CyclodrineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CyclopentolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
CycrimineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DexetimideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Dibutoline sulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DicyclomineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DicycloverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DiisopromineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DiphemanilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Diphemanil
  »metilsulfate
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DrotaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DuboisineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
DyphyllineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Emepronium (salts)T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Emepronium (salts)
  »bromide
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EthaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EthopropazineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EtomidolineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EtybenzatropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
EuphthalmineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Extrapyramidal antagonist NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
FenoverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
FlavoxateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
FlopropioneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
GefarnateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
GlycopyrrolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
GlycopyrroniumT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Glycopyrronium
  »bromide
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Hexasonium iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HexocycliumT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Hexocyclium
  »metilsulfate
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HomatropineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Homatropine
  »methylbromide
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HyoscineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HyoscyamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
HyoscyamusT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Hyoscyamus
  »dry extract
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
IsomethepteneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
IsopropamideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Isopropamide
  »iodide
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
LevsinT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MebeverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MeladrazineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MepenzolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Mepenzolate
  »bromide
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MepiperphenidolT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MethanthelineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methanthelinium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MethixeneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methscopolamine bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methylatropine nitrateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Methylbenactyzium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MetixeneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MilverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MoxaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
MydriacylT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Octatropine methyl-bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Otilonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Oxapium iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
OxybutyninT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
OxyphencyclimineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Oxyphenonium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PapaverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Parasympatholytic NECT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Penthienate bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PhenglutarimideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Pinaverium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Pipenzolate bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PiperidolateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PipethanateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Poldine metilsulfateT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PramiverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PridinolT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Prifinium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Pro-BanthineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ProcyclidineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ProfenamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ProfenilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
PropanthelineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Propantheline
  »bromide
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
RociverineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ScopolamineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Scopolia extractT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Smooth muscle relaxantT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
SpacolineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
SpasmolyticT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic
  »anticholinergics
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic
  »autonomic
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic
  »bronchial NEC
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic
  »quaternary ammonium
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Spasmolytic
  »skeletal muscle NEC
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
SulmetozineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ThiphenamilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TiemoniumT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tiemonium
  »iodide
T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TifenamilT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TigloidineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Timepidium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tiquizium bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TolperisoneT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
ToquizineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrasentineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TriampyzineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tricyclamol chlorideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Tridihexethyl iodideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrihexyphenidylT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrimebutineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Trimeprazine (tartrate)T44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TriperidenT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TrithiozineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TritiozineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TropacineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TropatepineT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
TropicamideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Trospium chlorideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6
Valethamate bromideT44.3X1T44.3X2T44.3X3T44.3X4T44.3X5T44.3X6

Patient Education


Medication Errors

Medicines treat infectious diseases, prevent problems from chronic diseases, and ease pain. But medicines can also cause harmful reactions if not used correctly. Errors can happen in the hospital, at the health care provider's office, at the pharmacy, or at home. You can help prevent errors by:

  • Knowing your medicines. When you get a prescription, ask the name of the medicine and check to make sure that the pharmacy gave you the right medicine. Make sure that you understand how often you should take the medicine and how long you should take it.
  • Keeping a list of medicines.
    • Write down all of the medicines that you are taking, including the names of your medicines, how much you take, and when you take them. Make sure to include any over-the-counter medicines, vitamins, supplements, and herbs that you take.
    • List the medicines that you are allergic to or that have caused you problems in the past.
    • Take this list with you every time you see a health care provider.
  • Reading medicine labels and following the directions. Don't just rely on your memory - read the medication label every time. Be especially careful when giving medicines to children.
  • Asking questions. If you don't know the answers to these questions, ask your health care provider or pharmacist:
    • Why am I taking this medicine?
    • What are the common side effects?
    • What should I do if I have side effects?
    • When should I stop this medicine?
    • Can I take this medicine with the other medicines and supplements on my list?
    • Do I need to avoid certain foods or alcohol while taking this medicine?

Food and Drug Administration


[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.